Company Directory / research
PrivateFor profitresearchChina
Ark Biosciences
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development
- Founded
- 2014 12 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $40M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
12 years old.
Reach
Website ranked #5,555,931 in the world for traffic, about 1k visits a month.
What it does
BiopharmaBiotechnologyHealth CarePharmaceutical
Funding, as listed
$40M currency not stated
- Rounds6
- LatestSeries d, Jul 2022
- Investors34, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Ark Biosciences, field by field. Contact details are held but never shown.
The company
- Name
- Ark Biosciences
- Type
- For profit
- Status
- Private
- Founded
- 2014
- Founders
- Jim Wu
- Industry
- research
- Categories
- Biopharma, Biotechnology, Health Care, Pharmaceutical
Where
- Country
- China
- Markets
- Asia-Pacific (APAC)
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #5,555,931
- Monthly web visits
- 1,299
Funding, as listed
- Total
- 40,086,000 (currency not stated)
- Rounds
- 6
- Latest round
- Series d
- Latest round date
- Jul 2022
- Investors
- 34
- Lead investors
- 4
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Ark Biosciences may be growing as it is mentioned in multiple news articles in the context of the idiopathic pulmonary fibrosis market and respiratory syncytial virus market, which are both showing signs of growth. The company is listed alongside other key players in the industry, indicating its active involvement and potential competitive presence in these markets. The idiopathic pulmonary fibrosis market, in which Ark Biosciences operates, is projected to grow at a CAGR of 6.6% during the study period of 2019-2032, suggesting a positive environment for companies in this space. Additionally, Ark Biosciences is noted in articles discussing the respiratory syncytial virus market, which is also expected to exhibit a rapid growth rate, further implying that the company is part of a growing industry sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in China.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 38,667 companies in China and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.